Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlorthalidone + amiloride is a fixed-dose combination of two oral antihypertensive agents used primarily for the treatment of high blood pressure (hypertension) and prevention of fluid retention (edema). Chlorthalidone is a thiazide-like diuretic that inhibits sodium-chloride symporter in the distal convoluted tubule of the nephron, leading to increased excretion of sodium, chloride, and water[1][3][5]. Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channel (ENaC) in the late distal tubules and collecting ducts, reducing sodium reabsorption while minimizing potassium loss[6]. The combination leverages chlorthalidone’s potent antihypertensive effect while counteracting its tendency to cause hypokalemia with amiloride’s potassium-sparing action. This combination has been shown to effectively reduce blood pressure and lower cardiovascular risk in patients with prehypertension or hypertension[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chlorthalidone + amiloride.